Tafamidis (Vyndaqel; Vyndamax): Why Two Products?

Our website now hosts a free article about tafamidis, a new drug in the US approved for treatment of adults with transthyretin-mediated amyloid cardiomyopathy, a progressive, life-threatening, under-diagnosed disease often referred to by its acronym (ATTR-CM). The drug was approved in 2 formulations with different brand names and different doses, both manufactured by Pfizer. Vyndaqel […]